Engene reports first quarter 2025 financial results and provides business update

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, or “engene” or the “company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended january 31, 2025, and provided a business update. “with the expansion of legend study sites into europe and asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a bla for detalimogene in mid-2026,” said ron cooper, chief executive officer o.
ENGN Ratings Summary
ENGN Quant Ranking